Apotex Pty Ltd v Les Laboratoires Servier (No 2)

Link copied
Case Copied 14 min read

FEDERAL COURT OF AUSTRALIA

Apotex Pty Ltd v Les Laboratoires Servier (No 2)

[2014] FCA 751

Citation: Apotex Pty Ltd v Les Laboratoires Servier (No 2) [2014] FCA 751
Parties: APOTEX PTY LTD ACN 096 916 148 v LES LABORATOIRES SERVIER and SERVIER LABORATORIES (AUST) PTY LTD
File number: NSD 51 of 2012
Judge: RARES J
Date of judgment: 26 May 2014
Legislation: Patents Act 1990 (Cth)
Cases cited: Apotex Pty Limited v Les Laboratoires Servier [2013] FCA 1426 referred to
Enka BV v E I Du Pont de Nemours & Company 1987 BP 13 referred to
Expo-Net Danmark A/S v Buono-Net Australia Pty Ltd (No 2) [2011] FCA 710 referred to
Multisteps Pty Ltd v Source & Sell Pty Ltd (No 2) [2013] 103 IPR 482 referred to
Novozymes A/S v Danisco A/S (No 2) [2013] FCAFC 55 referred to
Rural Press Limited v Australian Competition and Consumer Commission (2003) 216 CLR 53 applied

Date of hearing:

Date of orders:

26 May 2014

29 May 2014

Place: Sydney
Division: GENERAL DIVISION
Category: No catchwords
Number of paragraphs: 16
Counsel for the Applicant: Mr D K Catterns QC
Solicitor for the Applicant: Herbert Smith Freehills
Counsel for the Respondents: Mr A J L Bannon SC
Solicitor for the Respondents: Allens

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 51 of 2012

BETWEEN:

APOTEX PTY LTD  ACN 096 916 148
Applicant

AND:

LES LABORATOIRES SERVIER
First Respondent

SERVIER LABORATORIES (AUST) PTY LTD
Second Respondent

JUDGE:

RARES J

DATE OF ORDER:

29 MAY 2014

WHERE MADE:

SYDNEY

THE COURT DECLARES THAT:

1.The specification of Australian Patent 2003200700 does not comply with s 40(2)(a) of the Patents Act 1990 (Cth) because it fails to disclose the best method known to the patentee of performing the invention, being the following:

(a)The arginine salt has been made in the following manner. 12 g (32.56 mmol) of perindopril (free form) and 5.67 g (32.56 mmol) of L arginine were mixed and then dissolved in 150 ml of permuted water. The resulting mixture was filtered on a sintered filter to eliminate insoluble particles. The filtrated solution was then lyophilised (freeze dried). The residue was taken up again in 150 cc of anhydrous ethyl ether, stirred for two hours and passed through a sintered filter again, before being dried in a desiccator. This resulted in a white crystalline product weighing 16.58 g.

(b)The arginine salt has also been made in the following manner. 16.268 g (44.15 mmol) of free form perindopril was mixed with 7.306 g (41.94 mmol) of L arginine and 50 ml of permuted water. Those three ingredients were mixed in a 100 ml spherical flask, resulting in a semi-limpid solution. This was stirred for 15-20 minutes and evaporated until dry. The residue was retaken in a trituration using 150 ml of anhydrous ether. The solution was stirred overnight. Then the product was filtered under a vacuum, washed again with anhydrous ether and dried again in a desiccator under another…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Apotex Pty Ltd v Les Laboratoires Servier (No 2) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2014] FCA 751
Decision Date

CaseChat Overview and Summary

Apotex Pty Ltd v Les Laboratoires Servier (No 2) involved a dispute concerning the validity of a patent held by Servier. Apotex challenged the validity of Servier's patent for the arginine salt of perindopril, arguing that the patent specification failed to disclose the best method known to Servier for performing the invention. The matter was heard in the Federal Court of Australia.

The central legal issue was whether the patent complied with the disclosure requirements under section 40(2)(a) of the Patents Act 1990 (Cth). Specifically, the court had to determine whether Servier had disclosed the best method known to them for making the perindopril arginine salt. This involved examining the methods described in the patent and whether they were the best methods known to Servier at the time of filing the patent application.

The court found that the patent did not comply with the disclosure requirements, as it failed to describe the best method known to Servier for performing the invention. The court identified that Servier had knowledge of better methods for making the arginine salt, specifically the 1986 and 1991 methods, but these were not disclosed in the patent specification. The court concluded that the patent was invalid due to this failure of disclosure.

The court made a declaration that the patent did not comply with section 40(2)(a) of the Patents Act 1990 (Cth) because it failed to describe the best method known to Servier of performing the invention. The court also directed that the amendment application be brought to hearing.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

I am of opinion that I should make a declaration to reflect the conclusion at which I arrived. That declaration will give content to and indicate the gist of my findings: Rural Press Limited v Australian Competition and Consumer Commission (2003) 216 CLR 53 at 91 [89] per Gummow, Hayne and Heydon JJ. Their Honours there explained how appropriate content should be given to declarations: 216 CLR at 91-92 [90], [94]-[95].Conclusion For these reasons I will make a declaration that the patent does not comply with s 40(2)(a) of the Act because it failed to describe the best method known to the patentee of performing the invention, namely:“The arginine salt has been made in the following manner. 12 g (32.56 mmol) of perindopril (free form) and 5.67 g (32.56 mmol) of L arginine were mixed and then dissolved in 150 ml of permuted water. The resulting mixture was filtered on a sintered filter to eliminate insoluble particles. The filtrated solution was then lyophilised (freeze dried). The residue was taken up again in 150 cc of anhydrous ethyl ether, stirred for two hours and passed through a sintered filter again, before being dried in a desiccator. This resulted in a white crystalline product weighing 16.58 g.The arginine salt has also been made in the following manner. 16.268 g (44.15 mmol) of free form perindopril was mixed with 7.306 g (41.94 mmol) of L arginine and 50 ml of permuted water. Those three ingredients were mixed in a 100 ml spherical flask, resulting in a semi-limpid solution. This was stirred for 15-20 minutes and evaporated until dry. The residue was retaken in a trituration using 150 ml of anhydrous ether. The solution was stirred overnight. Then the product was filtered under a vacuum, washed again with anhydrous ether and dried again in a desiccator under another vacuum. This produced 21.29 g of white crystalline substance, being perindopril arginine.”16I have added emphasis in those descriptions to indicate the amendment that Servier made to its initial proposed wording for the passages it seeks be inserted on page 3A of the patent. Servier added the emphasised sentences to its proposed amendment following the argument on 26 May 2014. I will give directions to bring the amendment application to hearing.

Ratio Decidendi

Legal Principle Established

In the course of the interlocutory arguments as to how the amendment application could and should progress, the parties debated whether, if the amendment application were to proceed, it would be open to Apotex to rely on other possible methods, if any, that were known to Servier that were better than those, the subject of my earlier findings, in order to oppose the amendment under s 105. That raised the question of whether it was appropriate for me to make final orders that reflected, so far as it was possible, the reasons for my conclusions on the substantive points that I had reached so that any consideration of what further evidence or grounds of contest on the amendment application could be put in issue in that context. Both parties debated the effect of my findings as to the nature of Servier’s failure to disclose the best method as, in effect, assisting one or the other side’s position.Consideration In my opinion, the parties conducted the proceedings at trial on the basis of the particulars of invalidity as defining the matters that were substantively in issue. Critically, Apotex’ final version of its contention on Servier’s alleged failure to describe in the complete specification the best method known to it of performing the invention was that contained in pars 40-42 of its further amended particulars of invalidity. For present purposes, the critical issue that was propounded in those particulars, to which the parties drew attention in the course of argument today, arose from par 41, which stated, relevantly:“41Further, or in the alternative, if (which is not admitted) the process to make the perindopril arginine salt forms part of the inventive step described in the Arginine Patent, the specification does not describe the best method known to the Patentee of performing the invention as claimed in each claim of the Arginine Patent, being the means of making the perindopril arginine salt so as to obtain the alleged benefits of the invention.Particulars…(f)[Apotex’] case is that the Arginine Patent does not disclose the best method of performing the invention known to the Patentee because:1.the Arginine Patent discloses no method of carrying out the matters referred to in paragraph 41 above; and2the Patentee knew at the date of filing the application of the Arginine Patent of at least one method for performing the matters referred to in paragraph 41 above as set out in the confidential particulars at paragraph 49 of Annexure A to these Further Amended Particulars of Invalidity [being the 1986 and 1991 methods].(g)[Apotex] does not rely on any method which the Patentee may have had other than the method described in paragraph 49 of Annexure A to these Further Amended Particulars of Invalidity.” (emphasis added) Apotex confined its particularisation to the failure to disclose anything other than the 1986 and 1991 salification methods, as reflected in particular 41(g). That was because of the way in which it had drawn back from pursuing its application to amend its particulars of invalidity more broadly in late July 2013. Apotex made that application relatively shortly before the trial that was fixed to commence on 8 October 2013. Servier had argued, in resisting the amendment, that if Apotex’ then broadly-framed amendment on the issue of non-disclosure of best method were granted, Servier would have to conduct further investigations, review its own internal documents, consult with and obtain expert evidence and make further discovery, all of which would have made it impossible to maintain the hearing date. The common sense of that position appears to have informed the limitation that came to be contained in particular 41(g) so that Apotex relied at trial solely on Servier’s failure to disclose the 1986 and 1991 methods of salification in the complete specification in the patent. Thus, by relying on particular 41(g), Apotex abandoned any case wider than one that the only best method that Servier had an obligation to disclose was the 1986 and 1991 methods.